Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

57.83 +0.82 (+1.44%)
Streaming Delayed Price Updated: 11:36 AM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axonics Inc

< Previous 1 2 3 Next >
Axonics® Reports Second Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® to Report Second Quarter 2022 Financial Results on August 1
From Axonics, Inc.
Via Business Wire
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
From Axonics, Inc.
Via Business Wire
Axonics® Reports First Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics® to Report First Quarter 2022 Financial Results on May 5
From Axonics, Inc.
Via Business Wire
Axonics® Launches Direct to Consumer Television Advertising Campaign
From Axonics, Inc.
Via Business Wire
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
From Axonics, Inc.
Via Business Wire
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
From Axonics, Inc.
Via Business Wire
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
From Axonics, Inc.
Via Business Wire
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council
From Axonics, Inc.
Via Business Wire
Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics® Reports Third Quarter 2021 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County
From Axonics, Inc.
Via Business Wire
Axonics® to Report Third Quarter 2021 Financial Results on November 4
From Axonics, Inc.
Via Business Wire
Axonics® Provides Additional Update on Inter Partes Review Proceedings
From Axonics, Inc.
Via Business Wire
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in Upcoming Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics® Reports Second Quarter 2021 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors
From Axonics, Inc.
Via Business Wire
Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021
From Axonics, Inc.
Via Business Wire
Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator
From Axonics, Inc.
Via Business Wire
Axonics® Receives FDA Approval Further Expanding MRI Labeling
From Axonics, Inc.
Via Business Wire
Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval
From Axonics, Inc.
Via Business Wire
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
From Axonics, Inc.
Via Business Wire
Axonics® Announces Upsize and Pricing of Public Offering of Common Stock
From Axonics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.